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ABSTRACT: 
Improved understanding of the involvement of matrix-metalloproteinases (MMPs), 
including membrane-type MMPs (MT-MMPs), in human tumours has potential 
diagnostic, prognostic and therapeutic implications. We assessed the relationship 
between MT-MMP expression and clinicopathological parameters in human non-
small cell lung cancer (NSCLC) and histologically normal lung tissue by quantitative 
Real Time PCR (qRT-PCR). All MT-MMPs (MMPs 14-17, 24 and 25) were detected 
by qRT-PCR with significantly higher MMP-14, -15 and -17 expression observed in 
tumour relative to normal lung specimens. MMP-16 was undetectable in normal lung 
but expressed in 8% tumours. MMP-15 demonstrated significant overexpression in 
adenocarinomas relative to squamous cell carcinomas and normal lung tissue. MMP-
14 mRNA expression strongly correlated to MMP-14 proteolytic activity in 
preclinical tumour models, indicating that qRT-PCR may predict MMP-14 activity 
levels in NSCLC. These data suggest that MMP-14, -15 and -17 may be good markers 
of disease, or therapeutic targets for treatment of human NSCLC. 
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INTRODUCTION 
Non-small cell lung cancer (NSCLC) is the major cancer type in developed countries.  
Early stage NSCLC, without distant metastases or heavy regional nodal involvement, 
is often amenable to surgical resection and adjuvant chemotherapy. However, 
response to chemotherapy in NSCLC and prediction of tumour pathogenesis is often 
poor.  As a consequence, better understanding of the molecular pathology of NSCLC, 
determination of novel tumour markers and identification of targets for therapeutic 
exploitation are central to improving diagnosis and treatment. 
Matrix metalloproteinases (MMPs) are a family of at least 24 zinc-dependent 
endopeptidases, with the collective ability to degrade the basement membrane and all 
protein components of the extracellular matrix (ECM) (1-3). However, MMP activity 
is not restricted to ECM degradation and is essential for several processes involved in 
tumorigenesis including neovascularisation, induction of the epithelial-mesenchymal 
transition and regulation of growth factor and chemokine activity to name but a few 
(1-8).  The human MMP family is divided into eight distinct structural groups: five of 
which are secreted and three which are membrane-type MMPs (MT-MMPs) (2).  MT-
MMPs are membrane-tethered proteolytic enzymes and constitute the largest family 
of MMPs identified so far. The type 1 transmembrane structural class of MT-MMPs 
contains MMP-14 (MT1-MMP), MMP-15 (MT2-MMP), MMP-16 (MT3-MMP) and 
MMP-24 (MT5-MMP). The glycosyl phosphatidylinositol (GPI)-anchored structural 
group encompasses MMP-17 (MT4-MMP) and MMP-25 (MT6-MMP). Very little is 
known regarding the third MT-MMP group, the type II transmembrane MMPs, which 
contains only MMP-23 (cysteine-array MMP), a member structurally different from 
all other MMPs (9). Overexpression of MT-MMPs has been observed in many forms 
of cancer (10). The functions of MT-MMPs are known to include roles in activation 
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of other MMP family members, pericellular proteolysis, modulation of cellular 
signalling, cellular migration, regulation of cellular proliferation and apoptosis, the 
angiogenic response and regulation of tumour invasion metastasis (4, 10-13). Given 
the vast range of cellular processes influenced by the MT-MMPs, evaluation of their 
expression and activity in human tumours may be important in terms of diagnosis, 
prognosis and treatment. 
A number of recent studies have analysed genetic expression of MMP-14 in 
several human tumours types, including tumours of the breast, colon, head and neck, 
oral cavity, prostate and importantly for this study, pulmonary tumours including 
bronchopulmonary and NSCLC (14-20). The majority of these studies were 
semiquantitative and did not evaluate expression of the other MT-MMP members.  
Data regarding the expression of the MT-MMP subfamily in NSCLC is 
limited, therefore, the aim of the present study was to (a) assess the mRNA expression 
of the MT-MMPs by qRT-PCR in human preclinical tumour models and paired 
clinical human NSCLC tumour and histologically normal lung tissue; (b) to evaluate 
the correlation between MMP-14 mRNA expression and proteolytic activity. 
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MATERIALS AND METHODS 
Human Tissue Samples 
A total of 39 freshly resected and snap frozen specimens of NSCLC were used for this 
study. In addition, the study also included paired histologically normal human lung 
tissue specimens for 15 of the tumours, excised distant to the tumor mass. Patient ages 
ranged from 47 to 85 years (median 68 years). Informed consent was obtained from 
all patients prior to specimen collection and all patient details were anonymised to 
ensure confidentiality. All experiments were performed after first obtaining consent 
from the local research and ethics committee according to Medical Research Council 
Regulations. 
 The presence of tumour (or lack in terms of normal tissue specimens) and 
histopathological classification was confirmed by pathologists at Bradford Royal 
Infirmary, UK. The panel of tumours comprised 28 adenocarcinomas and 11 
squamous cell carcinomas (SCC) and a range of tumour stages (4 pT1; 30 pT2; 4 pT3 
and one pTx).   
 
Cell culture  
Cell lines were grown in monolayer culture in complete RPMI 1640 containing 10% 
v/v FBS, 1% v/v L-glutamine and 1% v/v sodium pyruvate (Sigma, Dorset, UK). All 
cultured cells were incubated at 37°C in a humidified atmosphere of 5% CO2. Cells 
were maintained in continuous exponential growth by passage every 5-7 days. Cells 
were either harvested when subconfluent by trypsinisation (Trypsin-EDTA; Sigma) 
and stored as pellets at -20°C. Cell lines used in these studies include; HT1080 
(fibrosarcoma); MCF-7 and MDA-MB-231 (breast carcinoma); HT29, BE, HCT116, 
COLO205, DLD1 (colorectal carcinoma); A549, H661, H460 (NSCLC); PC3 and 
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LNCAP (prostate carcinoma). All cell lines were obtained from ECACC (Sailsbury, 
Wiltshire, UK) or ATCC (Manassas, Virginia, USA). 
 
Human tumour xenografts 
Human tumour cell lines were xenografted in mice under a project license issued by 
the UK Home Office, following UKCCCR guidelines. Female mice (nu/nu from an 
inbred colony, B and K Universal, Hull, UK) 6-8 weeks old were implanted 
subcutaneously with 2-3 mm3 fragments of H460, A549 (NSCLC); MCF7 (breast 
carcinoma); BE, COLO 205, DLD1, HCT116, HT29 (colorectal carcinoma); PC3 
(prostate adenocarcinoma) or HT1080 (fibrosarcoma) tumors. Resultant tumors were 
removed, snap-frozen in liquid nitrogen and stored at -70°C. 
 
Determination of MMP-14 mRNA expression by semi-quantitative RT-PCR 
analysis 
TRI REAGENTTM (Sigma) was used to isolate RNA from cell pellets and tissue 
samples. Reverse transcription was performed using AdvantageTM RT-for-PCR kit 
(BD Bioscience, Oxford, UK) according to the manufacturer’s instructions. PCR was 
performed using the TitaniumTM Taq PCR kit (BD Bioscience) according to the 
manufacturer’s instructions and the primers described below (Invitrogen, Paisley, 
UK). Primers were based on previous studies (21, 22), and were: MMP-14 (sense) 5′-
CGC TAC GCC ATC CAG GGT CTC AAA-3′; MMP-14 (antisense) 5′-CGG TCA 
TCA TCG GGC AGC ACA AAA-3′; GAPDH (sense) 5′-CCA CCC ATG GCA AAT 
TCC ATG GCA-3′; GAPDH (antisense) 5′-TCT AGA CGG CAG GTC AGG TCC 
ACC-3′. PCR amplification of MMP-14 involved; initial denaturation of 94°C for 4 
min followed by 30 cycles of 94°C for 30 sec, 62°C for 30 sec and 72°C for 30 sec 
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PCR for GAPDH involved denaturation at 94°C for 4 min followed by 25 cycles of 
94°C for 30 sec, 60°C for 30 sec and 72°C for 90 sec.  All cycles were terminated 
with a 10 min incubation at 72°C to ensure complete elongation prior to incubation 
and storage at 4°C. RT-PCR products were separated through a 1% w/v agarose gel 
containing 0.01% v/v ethidium bromide and visualised under ultraviolet (UV) 
illumination. 
 
Quantification of MT-MMP expression by Real-Time RT-PCR (qRT-PCR) 
For qRT-PCR, RNA extraction was carried out as for RT-PCR.  For cDNA synthesis, 
a total of 1µg of total RNA was reverse transcribed using random hexamers 
(Amersham, Buckinghamshire, UK) and Superscript II reverse transcriptase 
(Invitrogen), according to supplier’s instructions. For PCR reactions, specific primers 
and fluorogenic probes for all MT-MMPs were designed using Primer Express 1.0 
software (Applied Biosystems, Warrington, UK) and synthesised by Applied 
Biosystems.  Where possible, to prevent the amplification of genomic DNA and to 
ensure the PCR signal was generated from cDNA, primers were generated with 
sequences within different exons, close to intron-exon boundaries. BLASTN searches 
(23) were conducted on all primer/probe nucleotide sequences to ensure gene 
specificity.  The 18S ribosomal RNA gene was used as an endogenous control to 
normalise for differences in the amount of total RNA in each sample, using previously 
validated procedures (24); 18S rRNA primers and probes were purchased from 
Applied Biosystems. PCR reactions were performed as described previously (24). To 
determine relative RNA levels within the samples, standard curves for the PCR 
reaction were prepared by using cDNA from one sample and making two-fold serial 
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dilutions covering the range equivalent to 20-0.625 ng RNA (for 18S analyses, the 
range was 4-0.125 ng). 
 
Determination of MMP-14 protein levels by ELISA assay 
MMP-14 protein activity levels were measured using the Biotrak Activity Assay 
System (Amersham Biosciences), carried out according to manufacturers instructions. 
Briefly, xenograft tissues were weighed, incubated for 15 min at 4ºC in membrane 
extraction buffer (50mM Tris-HCl pH 7.6, 1.5mM NaCl, 0.5mM CaCl, 1µM ZnCl, 
0.01% v/v Brij-35, 0.25% v/v Triton X-100), homogenised on ice and incubated for a 
further 15 min at 4ºC. The resultant supernatants and MMP-14 standards (ranging 
from, 0.125ng/ml - 32ng/ml) were incubated overnight at 4ºC on an anti-MMP-14 
antibody coated microplate.  Following incubation, all wells were washed (phosphate 
buffered saline containing 0.05% v/v Tween-20), the detection reagent added and the 
plate agitated and incubated at 37ºC for 6 hours.  The absorbance of each sample was 
read at 405nm and the concentration of MMP-14 in the samples calculated from the 
standard curve. 
 
Data Analysis 
For comparison of MT-MMP expression between NSCLC specimens and 
histologically normal tissue, the data did not satisfy normality or equal variance, so 
nonparametric statistical tests were used.  The Mann-Whitney U test was carried out 
to compare malignant and non-malignant samples. For all tests, a P-value of less than 
0.01 was considered statistically significant. 
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RESULTS 
Expression of MT-MMPs in human tumour cell lines and xenografts 
The expression of the MT-MMPs was assessed in a panel of human cell lines and 
human tumour xenografts representing several different human tumour types by qRT-
PCR. All MT-MMPs were detected successfully (Figure 1) and were in agreement 
with expression observed by semi-quantitative RT-PCR (data not shown). MMP-14 
and MMP-15 were expressed at high levels in all the tumour types represented in the 
screen (Figure 1). MMP-16, -17, -24 and -25 demonstrated differential expression 
throughout the preclinical tumour panel suggesting potential associations between 
these MMPs and tumour origin or tumour type (Figure 1). In contrast to the other MT-
MMPs, the type II transmembrane MMP, MMP-23, was expressed at relatively low 
levels in both lung cell lines and xenografts (Figure 1) and was not therefore analysed 
in subsequent studies.  
 
MT-MMP expression in NSCLC specimens and histologically normal lung tissue 
The high level and range of MT-MMP expression observed in preclinical models of 
lung cancer (Figure 1) led us to evaluate the expression of MMP-14, -15, -16, -17, -24 
and -25 (MT[1-6]-MMP) in clinical specimens of NSCLC and associated 
histologically normal lung tissue by qRT-PCR. MMP-14 was expressed in 100%  
NSCLC tumour specimens analysed in our study at levels significantly higher than 
that observed in histologically normal lung tissue (Figure 2; P< 0.01). Of the other 
type I transmembrane MMPs, MMP-15 demonstrated significantly higher expression 
in NSCLC compared to histologically normal lung tissue (Figure 2; P< 0.01), MMP-
16 was absent or expressed at extremely low levels in all clinical specimens evaluated 
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(Figure 2) and MMP-24 demonstrated no significant difference in expression between 
NSCLC and histologically normal lung tissue (Figure 2; P = 0.5).  
 The GPI-anchored MT-MMPs, MMP-17 and -25 were also expressed in both 
NSCLC and the associated histologically normal lung tissue (Figure 2), although a 
significant difference between tumour and normal was detected for MMP-17 but not 
MMP-25 (P< 0.01 and P= 0.9, respectively) 
 
Relationship between MT-MMP expression and tumour pathology 
In contrast to the other MT-MMPs evaluated, expression of MMP-15 demonstrated 
differential expression between NSCLC tumour subtypes (Figure 3).  In addition to 
being significantly higher than that observed in histologically normal lung tissue (p< 
0.01), levels of MMP-15 in adenocarcinoma (n=28) were also significantly higher 
than that detected in squamous cell carcinoma (SCC) (n=11; p< 0.01) (Figure 3). In 
contrast, although MMP-14 also demonstrated significantly higher expression in 
NSCLC compared to histologically normal lung, no significant difference was 
observed between tumour types (Figure 3). 
Although expression of MMP-14, -16, -17, -24 and -25 were detected in 
human NSCLC, no significant correlation was observed between the expression of the 
individual MMPs and either tumour stage (pT status), tumour grade or presence of 
lymph node invasion (pN status) (Data not shown). 
 
Correlation between MMP-14 activity and MMP-14 qRT-PCR expression 
Levels of proteolytically active MMP-14 were determined in human tumour cell lines 
and xenografts using the fluorogenic MT1-MMP (MMP-14) Biotrak assay. MMP-14 
activity levels detected using this assay ranged from 1.1–0.02 ng MMP-14 per mg 
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tissue, with the highest levels detected in HT1080 (1.12±0.10 ng MMP-14 per mg 
tissue) and lowest in H460 (0.02±0.01 ng MMP-14 per mg tissue) (Figure 4). 
Comparison of MMP-14 activity levels with MMP-14 mRNA expression, as 
measured by qRT-PCR, demonstrated an excellent correlation between the levels of 
active MMP-14 and MMP-14 mRNA expression in both cell lines (data not shown) 
and xenografts (Figure 4; R2 = 0.9).  
 
DISCUSSION 
MMPs are central regulators in the tumorigenic process and the major proteases 
involved in ECM breakdown and remodelling (1). The original hypothesis that MMPs 
were involved purely with ECM degradation and consequently tumour invasion and 
metastasis was demonstrated to be too simplistic and the MMPs are now known to be 
a major force in the phenotypic evolution of cancer (25). Growth-factor receptors, cell 
adhesion molecules, chemokines, cytokines, apoptotic ligands, and angiogenic factors 
are just some examples of the diversity of substrates targeted by the MMPs (3). 
Identification of proteolytic enzyme expression and localisation in human cancers 
is critical in understanding the characteristics of individual cancer types, referred to as 
the cancer degradome (26).  Identification of specific MMPs important in the various 
stages of cancer progression, will lead to improved understanding of different cancers 
and may represent new markers of disease or may lead to the identification and 
validation of new therapeutic targets. 
The purpose of this study was to comprehensively analyse expression of the 
membrane-type MMP (MT-MMP) subfamily in human NSCLC and to evaluate the 
relationship between genetic expression of MMP-14 and the presence of active MMP-
14. We have shown differential expression of these MMPs in NSCLC and 
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demonstrated significantly higher levels of several family members in tumours 
compared to histologically normal lung tissue (Figure 2). 
MMP-14 was expressed in 100% NSCLC tumour specimens analysed in our 
study (Figure 2). The high levels of MMP-14 expression quantified in NSCLC in this 
study reinforces previous studies implicating increased MMP-14 expression in lung 
cancer by semi-quantitative in-situ hybridisation and cDNA array analysis (15, 27). 
Although in our study MMP-14 was detected at low levels in histologically normal 
lung tissue, expression was significantly higher in NSCLC specimens (p < 0.01; 
Figure 2). The elevated levels of MMP-14 we observed in NSCLC demonstrated no 
relationship to tumour stage, tumour grade, presence of tumour lymph node invasion 
or differential between histological tumour type (data not shown). 
Data focussing on the expression of MMP-15 (MT2-MMP) in NSCLC is 
sparse. As for MMP-14, MMP-15 displayed a statistically significant difference 
(P<0.01) in expression between tumour tissue and histologically normal lung (Figure 
2). This is supported by a previous study in which MMP-15 levels were suggested to 
be higher in adenocarcinoma cells than either type II alveolar cells or bronchiolar 
epithelial cells (28). Further to demonstrating increased MMP-15 expression in 
NSCLC relative to histologically normal lung tissue, we have also shown significantly 
higher expression in lung adenocarcinoma relative to lung SCC (P<0.01; Figure 3), a 
previously unreported observation. No such differential was observed for MMP-14 
(Figure 3). This strongly suggests that MMP-15 may be a viable marker for molecular 
diagnostics of NSCLC and as such warrants further investigation. Similarly, the 
suggestion that MMP-15 has an anti-apoptotic mechanism and may connect tumour 
metastasis and apoptotic resistance (11) is also of relevance to our study and worthy 
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of further investigation due to the high levels of MMP-15 we observed in NSCLC 
specimens. 
There is very little data concerning the expression of MMP-16, MMP-17, 
MMP-24 or MMP-25 (MT(3-6)-MMP) in human tumours and no specific evidence 
for their involvement in NSCLC.  MMP-16 was absent or expressed at extremely low 
levels in all clinical samples evaluated (Figure 2). It is interesting to note the 
expression profile of MMP-16 in preclinical human tumour models, the differential in 
expression observed between tumour types and between cells grown in vitro or as in 
vivo tumour xenografts (Figure 1). These observations could be the consequence of 
the degree of xenograft vascularisation or invasiveness, as supported by the recent 
associations between MMP-16 and both tissue vascularisation (29) and β-catenin 
mediated tumour invasion (30). Identification of any such relationship and their 
clinical significance have yet to be undertaken. In the case of the lung cell lines, 
MMP-16 was detected in the H460 cells grown in vitro but not in vivo (Figure 1), 
which is interesting in light of the fact that MMP-16 was absent in the majority of 
NSCLC samples.  
Increased expression of MMP-17 was observed in NSCLC and did 
demonstrate a statistically significant difference from histologically normal lung 
(Figure 2).  Due to the low levels of MMP-17 detected in the majority of samples, 
caution should be adopted in the significance of this difference and the relationship to 
protein levels.  MMP-24 and MMP-25 display differential expression between tumour 
and normal tissue although these failed to reach statistical significance (P = 0.5 and P 
= 0.9, respectively). Whilst we would predict that the expression of the MT-MMPs 
might be related to the stage and development of cancers due to their known 
involvement in metastasis, cell migration and activation of other MMP family 
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members, no correlation was observed between tumour stage, grade or lymph node 
invasion and the expression of individual MT-MMPs (data not shown). These 
findings are perhaps surprising given the well documented role of the MMPs, 
including MT-MMPs, in various stages of cancer development and tumour spread 
(13) . 
The excellent correlation (R2= 0.9) noted in this study between qRT-PCR and 
activity data for MMP-14 indicates that qRT-PCR is a proportional measurement of 
the level of MMP-14 protein present in a sample (Figure 4). This correlation thereby 
adds value to the qRT-PCR clinical sample data for the MT-MMPs. Due to the nature 
of this assay, it does not take into account any potential intrinsic regulation of MT-
MMP activity, such as by TIMPs, and may therefore signify the levels of MMP-14 
protein and total potential MMP-14 activity rather than actual activity. Since both the 
qRT-PCR and activity assay capture a single snapshot in the tumour, it would be 
interesting to assess the potential changes in expression and activity during 
tumourigenesis and tumour progression. In support of this, it would be desirable to 
evaluate the expression and sub-tumoral distribution of specific MT-MMPs using in 
situ  hybridisation or immunohistochemistry, should specific and appropriate 
antibodies become available. In addition, it would also be interesting to differentiate 
the levels of actual MMP-14 activity from total potential MMP-14 activity in this 
context, to further assess MMP-14 as a disease marker or target for therapeutic 
exploitation in NSCLC. 
Currently there are no assays available to study the activity of MT(2-6)MMP 
in samples and we have not found any commercially available antibodies suitable for 
the development of such assays (data not shown).  It will be important to investigate 
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the relationship between qRT-PCR data and protein expression for all MT-MMPs to 
ascertain if a similar relationship is observed as is seen for MMP-14.  
This study is the first analysis of all 6 MT-MMPs in NSCLC clinical 
specimens. Our data identifies a number of the MT-MMPs as being differentially 
expressed in NSCLC relative to histologically normal lung tissue, suggesting roles in 
tumourigenesis and/or as markers of disease.  Using an MMP-14 activity assay, we 
have demonstrated the value of qRT-PCR as a predicator of protein expression.  In 
summary, this study indicates the potential use of MMP-14 and MMP-15 as disease 
markers and therapeutic targets. 
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Figure Legends: 
 
Figure 1. MMP expression in human tumour cell lines and xenografts as measured by 
quantitative RT- PCR (qRT-PCR). Values of gene output are probe, and therefore 
gene specific, thus precluding comparison of expression between genes. 
 
Figure 2.  Differential expression of the MT-MMP subfamily in human NSCLC and 
histologically normal lung tissue by qRT-PCR. Values are after normalisation to 18S-
rRNA and are therefore gene specific. Expression data is plotted as mean expression ± 
Standard Error (S.E.). 
 
Figure 3. Elevated expression of MMP-15 by qRT-PCR in lung adenocarcinomas 
compared to SCC (P<0.01) and histologically normal lung (P<0.01). 
 
Figure 4. MMP-14 activity levels determined by ELISA (A) correlate strongly to 
MMP-14 expression by qRT-PCR (B), as measured in human tumour xenografts.  A 
close correlation (R2=0.9) is observed between activity and expression (C). 
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